The reasons aren't fully clear, but overdose deaths are down in Kern, US
According to KCSO, there were 189 fentanyl-related overdose deaths in Kern County in 2024, down from 297 in 2023, a roughly 36% decline.
The decline is part of a broader trend nationally. Opioid overdose deaths declined sharply from 2023-2024, according to provisional data from the Centers for Disease Control and Prevention.
According to the CDC, 48 states and the District of Columbia all saw decreases in overdose deaths from December 2023 to 2024, a 26% decrease nationwide. California's reported overdose deaths dropped by 24%, the most of any West Coast state.
Only Nevada and South Dakota saw an increase in overdose deaths, both by less than 4%.
It's not entirely clear what's driving the decline, and experts are pointing to a range of factors.
"Over the past, I'd say this calendar year, we have seen an increase in the people who are coming into our treatment system," said Ana Olvera, an administrator with Kern Behavioral Health and Recovery Services.
"More people have accessed our treatment system than in years past, even coming out of COVID, which is a good sign for us," Olvera said.
The increased availability of treatment programs and the overdose reversal drug naloxone were likely contributors to the decrease, she said, as well as reduced stigma about seeking treatment.
Olvera also pointed to the passage of Proposition 36, which increased penalties for certain crimes.
"Just from that — working with the courts and people who are eligible for this program that have a treatment-mandated felony — we have seen an increase of folks who are eligible and who come into our system of care," Olvera said.
BHRS and other health care providers have increased their treatment options, Olvera said. The county's 24-hour substances-use-disorder hotline, which helps connect people with treatment, has seen higher call volume over the years, she said.
"The call center is how most people access treatment in our substance use system," Olvera said.
The average number of calls has increased from 908 in the 2018-2019 fiscal year to 1,272 in 2023-2024. From July 2024 to April of this year, there were 1,061 calls.
There's no doubt overdose deaths are dropping, but exactly why is still a matter of conjecture.
The Opioid Data Lab at the University of North Carolina at Chapel Hill tracks information related to opioids and its researchers have said there's no single explanation for such a steep, nationwide decline in overdose deaths.
"Ascribing a single national explanation for the drop in overdoses is not grounded in data," the lab said in a February analysis.
Even with the large decline in deaths, the mortality rate from drug overdoses remains high, with most states still recording death rates higher than before the COVID-19 pandemic.
Data from the CDC and the California Department of Public Health shows overdose deaths peaking in 2023 before dropping sharply in 2024.
According to CDPH, Kern County's opioid-related overdose deaths reached an all-time high of 321 in 2023. That was up from 308 in 2022 and 274 in 2021.
As of April 30, Kern had seen 50 fentanyl-related deaths so far this year, according to KCSO.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
US: RFK Jr. risking 'nation's health' with misinformation
Over 750 US Department of Health and Human Services staff on Wednesday called on Secretary Robert F. Kennedy Jr. to ensure health workers' safety. A signed open letter said health staff were being put at risk by misleading claims about vaccines and infectious diseases and came in the wake of this month's deadly shooting at Centers for Disease Control and Prevention (CDC) buildings in Atlanta. What was said in the letter? The open letter said Kennedy "is complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information," and implored the health chief to change his stance. "The deliberate destruction of trust in America's public health workforce puts lives at risk. We urge you to act in the best interest of the American people — your friends, your families, and yourselves," the letter said. Wednesday's letter was signed by former CDC leaders such as Anne Schuchat, a former principal deputy director, although many who signed did so anonymously for fear of retaliation. CDC gun attack 'not random' On August 8, a man fired nearly 200 rounds at six CDC buildings, killing a police officer in the process before taking his own life. Investigators said that notes found at the gunman's residence suggested discontent with the COVID-19 vaccine, blaming it for making him sick. Those who signed the open letter said that the attack "was not random," and pointed to "growing mistrust in public institutions, driven by politicized rhetoric that has turned public health professionals from trusted experts into targets of villainization — and now, violence." Kennedy has been a long-time vaccine skeptic and notably removed all 17 members of the CDC's vaccine advisory panel last June. He announced earlier this month that research funding for mRNA vaccines would be slashed. Kennedy argued that the vaccines had failed to protect effectively against infections like COVID and flu. Edited by: John Silk
Indianapolis Star
10 minutes ago
- Indianapolis Star
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.
Yahoo
10 minutes ago
- Yahoo
New Covid wave warning as cases in hospital patients soar by 31% in a fortnight
Covid cases in hospital patients have jumped by almost a third in a fortnight - sparking concerns of a new Covid wave. The number of hospital patients with respiratory symptoms testing positive for the virus has increased from 5.8 per cent on 26 July to 7.6 per cent on 10 August, according to the UK Health Security Agency (UKHSA). That marks an increase of 31 per cent in just 15 days. This percentage is known as the positivity rate and it is much higher among hospital patients with symptoms than the general public. The rise in cases in hospitals could be an indication the country is facing a new wave of infections, with epidemiologists suggesting soaring cases could be a cause for concern. 'This rise in cases reinforces the fact that the virus is still circulating and is capable of spreading,' Professor Lawrence Young, a virologist at Warwick University told The Independent. He added: 'A particular concern is the impact on infection levels as people return to work and school after the holiday season and the effect of cooler weather. This coupled with new virus variants and restricted access to free vaccines over the Autumn period is worrying.' But experts stress it is difficult to get an accurate picture as people no longer routinely test for the virus. Infectious disease expert Professor Paul Hunter, at University of East Anglia, explained that infection numbers have been drifting up and down for most of the year and he expects cases to rise as we approach the end of the year. 'We will see further increases but against a continuing declining general trend in hospitalisation and deaths. As to how many infections are occurring in the community. I have no idea as we only really test people in hospitals now,' Professor Hunter told the Independent. 'As to how many infections are occurring in the community, I have no idea as we only really test people in hospital now,' he added. Although this spike of 7.6 per cent is still lower than it was for most of the pandemic, it's much higher than it was in January when it was 2.2 per cent. In July last year, cases hit 16.6 per cent and 14.6 per cent in October last year, according to UKHSA data. The Covid vaccine is usually offered on the NHS in spring and early winter to people who need extra protection from the virus. But this year almost 13 million fewer people will be offered the booster jab. The Government is no longer offering the jab to pensioners aged 65 to 74, nor are they offering it to pregnant women or people with chronic heart disease or liver disease. This autumn the vaccine will be offered to adults over 75, residents in care homes for older adults and those who are immunosuppressed over the age of six months.
